In Wednesday’s Wall Street session, Agilon Health Inc (NYSE:AGL) shares traded at $3.39, down -23.99% from the previous session.
AGL stock price is now -18.93% away from the 50-day moving average and -5.81% away from the 200-day moving average. The market capitalization of the company currently stands at $1.40B.
With the price target maintained at $5, Citigroup recently Upgraded its rating from Neutral to Buy for Agilon Health Inc (NYSE: AGL). On April 08, 2025, Bernstein Upgraded its previous ‘Mkt Perform’ rating to ‘Outperform’ on the stock keeping its target price maintained at $8.50, while ‘Citigroup’ rates the stock as ‘Neutral’
In other news, McLoughlin Karen, Director bought 25,000 shares of the company’s stock on Dec 13 ’24. The stock was bought for $55,085 at an average price of $2.20. Upon completion of the transaction, the Director now directly owns 73,166 shares in the company, valued at $0.25 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 11 ’24, Director Battaglia Silvana bought 25,062 shares of the business’s stock. A total of $50,269 was incurred on buying the stock at an average price of $2.01. This leaves the insider owning 66,144 shares of the company worth $0.22 million. A total of 26.86% of the company’s stock is owned by insiders.
During the past 12 months, Agilon Health Inc has had a low of $1.50 and a high of $7.73. As of last week, the company has a debt-to-equity ratio of 0.08, a current ratio of 1.20, and a quick ratio of 1.20.
The net profit margin was -4.25% and return on equity was -42.95% for AGL. The company reported revenue of $1.53 billion for the quarter, compared to $1.6 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -4.46 percent.
